Close Menu

financial results

Adaptive said that Q4 clinical testing volume for its ClonoSeq sequencing assay for minimal residual disease increased 66 percent to 3,218 tests.

Opko recorded $177.9 million in service revenues, $32 million in product revenues, and $14.4 million from licensing and the transfer of intellectual property revenues.

The increase in total revenues was driven primarily by sales of Natera's Panorama and Horizon reproductive health tests.

Billable test volume for the company's ConfirmMDx prostate cancer test fell 5 percent year over year, but global volume for its SelectMDx test rose 61 percent.

The firm posted $29.7 million in revenues, up about 15 percent from $25.8 million in Q4 2018 and slightly above the analysts' average estimate of $29.5 million.

The firm placed 45 of its T2Dx diagnostics instruments in 2019, but plans to reduce that number in 2020 to focus on instrument utilization.

The firm said its revenues for the three months ended Dec. 31, 2019 were $62.9 million compared to $32.9 million in the same quarter of 2018.

Invitae reported $66.3 million in revenues for the fourth quarter, which fell short of the consensus Wall Street estimate of $68.1 million.

The firm saw strong increases in international HIV sales of its OraQuick HIV Self-Test product in the quarter.

For the three months ended Jan. 31, the firm's revenues rose to $1.36 billion from $1.28 billion, beating analysts' average estimate of $1.35 billion.

Pages